Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Intensive peri-operative use of factor VIII and the Arg593-->Cys mutation are risk factors for inhibitor development in mild/moderate hemophilia A.

Journal of thrombosis and haemostasis : JTH - 1 Jun 2009

Eckhardt C L, Menke L A, van Ommen C H, van der Lee J H, Geskus R B, Kamphuisen P W, Peters M, Fijnvandraat K

Abstract excerpt

BACKGROUND: A severe and challenging complication in the treatment of hemophilia A is the development of inhibiting antibodies (inhibitors) directed towards factor VIII (FVIII). Inhibitors aggravate bleeding complications, disabilities and costs. The etiology of inhibitor development is incompletely understood. OBJECTIVES: In a large cohort study in patients with mild/moderate hemophilia A we evaluated the role...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Arginine
Share to Autoantibodies

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cysteine

Share to Factor VIII

Share to Hemophilia A

Share to Longitudinal Studies

Share to Severity of Illness Index

Share to Young Adult

Source

Identifiers

PMID: 19548904
DOI: 10.1111/j.1538-7836.2009.03357.x

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Intensive peri-operative use of factor VIII and the Arg593-->Cys mutation are risk factors for inhibitor development in mild/moderate hemophilia A.PMID 19548904Read ↗

In non-severe hemophilia A the risk of inhibitor after intensive factor treatment is greater in older patients: a case-control study.Semantic proximity Read ↗

Inhibitors in mild/moderate haemophilia A: an update.Semantic proximity Read ↗

HLA class II genotype and factor VIII inhibitors in mild haemophilia A patients with an Arg593 to Cys mutation.Semantic proximity Read ↗

Correlation between factor VIII genotype and inhibitor development in hemophilia A.Semantic proximity Read ↗

Genetic risk factors for inhibitors to factors VIII and IX.Semantic proximity Read ↗

Treatment related factors and inhibitor development in children with severe haemophilia A.Semantic proximity Read ↗

Influence of the type of F8 gene mutation on inhibitor development in a single centre cohort of severe haemophilia A patients.Semantic proximity Read ↗

Environmental and genetic factors influencing inhibitor development.Semantic proximity Read ↗

Inhibitor development in hemophiliacs: the roles of genetic versus environmental factors.Semantic proximity Read ↗

Assessing risk factors: prevention of inhibitors in haemophilia.Semantic proximity Read ↗

Variation in baseline factor VIII concentration in a retrospective cohort of mild/moderate hemophilia A patients carrying identical F8 mutations.Semantic proximity Read ↗

Factor VIII gene (F8) mutation and risk of inhibitor development in nonsevere hemophilia A.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.